Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses

This publication has 38 references indexed in Scilit:

• Twist and Shout: One Decade of Meta-Analyses of Erythropoiesis-Stimulating Agents in Cancer Patients
  Acta Haematologica, 2010
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
  British Journal of Cancer, 2010
• Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
  Gynecologic Oncology, 2008
• Patient and caregiver time burden associated with anaemia treatment in different patient populations
  Supportive Care in Cancer, 2006
• Efficacy and Safety Analysis of Epoetin Alfa in Patients With Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
  Journal of Clinical Oncology, 2005
• O-154 Impact of maintaining Hb with epoetin alfa on time toprogression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients
  Lung Cancer, 2005
• The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
  European Journal of Cancer, 2004
• Measuring inconsistency in meta-analyses
  BMJ, 2003
• O-253 Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients
  Lung Cancer, 2003
• Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
  British Journal of Cancer, 1999